Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pimodivir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 5/20 | 1.00 |
| ▸ | GSK3B | P49841 | 5/20 | 1.00 |
| ▸ | FLT3 | P36888 | 5/20 | 0.83 |
| ▸ | JAK2 | O60674 | 4/20 | 0.83 |
| ▸ | SRC | P12931 | 4/20 | 0.83 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.71 |
| ▸ | KDR | P35968 | 3/20 | 0.71 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.71 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.71 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.71 |
| ▸ | PRKACA | P17612 | 2/20 | 0.71 |
| ▸ | PLK1 | P53350 | 2/20 | 0.71 |
| ▸ | CDK2 | P24941 | 1/20 | 0.71 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pimodivir SCHEMBL29351171 | 1.00 | GSK3A (1.00) | GSK3AGSK3BFLT3JAK2SRC | |
| Pimodivir SCHEMBL20150447 | 1.00 | GSK3A (1.00) | GSK3AGSK3BFLT3JAK2SRC | |
| Pimodivir SCHEMBL30321183 | 1.00 | GSK3A (1.00) | GSK3AGSK3BFLT3JAK2SRC | |
| Pimodivir SCHEMBL31554841 | 1.00 | GSK3A (1.00) | GSK3AGSK3BFLT3JAK2SRC | |
| Pimodivir SCHEMBL16728442 | 1.00 | GSK3A (1.00) | GSK3AGSK3BFLT3JAK2SRC | |
| Pimodivir SCHEMBL2128140 | 1.00 | GSK3A (1.00) | GSK3AGSK3BFLT3JAK2SRC | |
| Pimodivir SCHEMBL15723339 | 1.00 | GSK3A (1.00) | GSK3AGSK3BFLT3JAK2SRC | |
| Pimodivir SCHEMBL10304158 | 1.00 | GSK3A (1.00) | GSK3AGSK3BFLT3JAK2SRC | |
| Pimodivir SCHEMBL16728380 | 1.00 | GSK3A (1.00) | GSK3AGSK3BFLT3JAK2SRC | |
| Pimodivir SCHEMBL17771569 | 1.00 | GSK3A (1.00) | GSK3AGSK3BFLT3JAK2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3555095-B1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2023-04-12 | — | — | EP | disclosed |
| WO-2023009754-A2 | PROTEIN-ANTIVIRAL COMPOUND CONJUGATES | REGENERON PHARMACEUTICALS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-11225477-B2 | Inhibitors of influenza virus replication, application methods and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-01-18 | — | — | US | disclosed |
| US-10987354-B2 | Inhibitors of influenza virus replication and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-04-27 | — | — | US | disclosed |
| WO-2021038480-A1 | COMBINATIONS FOR TREATING INFLUENZA VIRUS | Janssen Pharmaceuticals, Inc. (US) | 2021-03-04 | — | — | WO | disclosed |
| US-20210008072-A1 | FORMULATIONS OF AZAINDOLE COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-01-14 | — | — | US | disclosed |
| US-10874673-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200397784-A1 | FORMULATIONS OF AZAINDOLE COMPOUNDS | JANSSEN PHARMACEUTICALS INC (US) | 2020-12-24 | — | — | US | disclosed |
| WO-2020256820-A1 | FORMULATIONS OF AZAINDOLE COMPOUNDS | Janssen Pharmaceuticals, Inc. (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200299294-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-09-24 | — | — | US | disclosed |
| US-20190151314-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2019-05-23 | — | — | US | disclosed |
| WO-2018108125-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-06-21 | — | — | WO | disclosed |
| EP-3068782-B1 | METHODS OF PREPARING INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMA (US) | 2018-05-23 | — | — | EP | disclosed |
| WO-2018033082-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-02-22 | — | — | WO | disclosed |
| US-9808459-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-11-07 | — | — | US | disclosed |
| US-9771361-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-09-26 | — | — | US | disclosed |
| WO-2017097234-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-06-15 | — | — | WO | disclosed |
| US-20170100400-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2017-04-13 | — | — | US | disclosed |
| EP-2651938-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Incorporated (US) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012083122-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299294-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | POLRMT, EIF2AK2, POLM | GSK3A 372/4885GSK3B 277/4885FLT3 444/4885 |
| US-20210008072-A1 | FORMULATIONS OF AZAINDOLE COMPOUNDS | H1-0, H1-5, H1-2 | GSK3A 1966/4885GSK3B 2194/4885FLT3 2993/4885 |
| US-20200397784-A1 | FORMULATIONS OF AZAINDOLE COMPOUNDS | IDO1, IL5, GCG | GSK3A 826/4885GSK3B 752/4885FLT3 2153/4885 |
| US-20190151314-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, IRF3, ACE2 | GSK3A 1026/4885GSK3B 1005/4885FLT3 1071/4885 |
| US-10987354-B2 | Inhibitors of influenza virus replication and uses thereof | ZC3HAV1, MAVS, POLRMT | GSK3A 334/4885GSK3B 241/4885FLT3 219/4885 |
| US-10874673-B2 | Inhibitors of influenza viruses replication | ACE, IRF3, ACE2 | GSK3A 1026/4885GSK3B 1005/4885FLT3 1071/4885 |
| US-11225477-B2 | Inhibitors of influenza virus replication, application methods and uses thereof | POLRMT, EIF2AK2, POLM | GSK3A 372/4885GSK3B 277/4885FLT3 444/4885 |
| US-20170100400-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, IRF3, ACE2 | GSK3A 1026/4885GSK3B 1005/4885FLT3 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.